KTTA Stock Catalyst: Pasithea Therapeutics Completes Cohort 7 in Phase 1 Trial of PAS-004

Nov 25, 2025 · 7:59pm ET

Positive safety, pharmacokinetic, and pharmacodynamic data reported.

Max move

+243.1%

High of day $0.07

Sparker timei

7:59pm ET

KTTA · Nov 25, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced the completion of Cohort 7 in its ongoing Phase 1 trial of PAS-004 for advanced cancer patients. The trial reported positive safety, pharmacokinetic (PK), and pharmacodynamic (PD) data.

The trial continues to evaluate the safety and efficacy of PAS-004 in patients with advanced solid tumors. Pasithea Therapeutics has a free float of 7,411,900 shares and 22,398,900 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KTTA sparks.

Download Sniper App →

Catch the next KTTA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →